ABT heads into the back half of April with insiders putting money to work at a stock that has fallen nearly 26% year-to-date — even as a wave of analyst target cuts follows the company's Q1 earnings miss.
The most striking signal this week is the insider buying cluster. On April 27, independent director Daniel Starks purchased 10,000 shares at $92.65, committing just over $926,000. Two trading days earlier, CFO Philip Boudreau added 2,200 shares at $91.50. Together those two purchases represent the most concentrated buying from company insiders in recent months, and they come against a backdrop of March executive sales at prices between $115 and $116 — a gap that suggests those same insiders now see the stock as meaningfully cheaper. The 90-day net insider position is modestly positive at roughly $10.9 million in net value bought, a sign the purchase tide has started to turn even as the stock remains well below its year-start levels.
The Street's reaction to Q1 results tells a similar but more cautious story. The earnings print on April 16 saw the stock drop 4.7% on the day and 8.9% over the following week, driven by softer diabetes-segment growth tied to a delayed international tender renewal and a weaker respiratory season. What followed was a broad analyst target-cutting exercise: BofA Securities, Stifel, and Benchmark all lowered targets to around $120, while Piper Sandler and Oppenheimer dropped to $115, and Barclays trimmed to $143. Crucially, none of them downgraded. The consensus remains a hold with outperform-leaning overtones — seven holds and five outperform-equivalent ratings — and the mean price target near $118.64 implies roughly 26% upside from the current $93.86. BTIG reiterated its $131 Buy target as recently as April 27, the day after the dust settled. Bulls point to ABT's diversified model, its innovation pipeline in medical devices, and the probability that the tender delay is a one-quarter item. Bears flag regulatory risk in medical devices, reimbursement pressure, and the risk that the diabetes franchise's deceleration is more structural than seasonal.
Valuation has re-rated meaningfully lower over the past month. The trailing P/E has compressed by about 1.5 turns to 16.5x, and price-to-book is down roughly 0.1x to 3.3x. EV/EBITDA of 12.3x is up slightly on the week as the share price recovered, but remains near multi-year lows for the stock. The RSI14 of 34.8 puts ABT in technically oversold territory, not yet at extreme lows but well below neutral. The factor score for analyst recommendation differential ranks in the 94th percentile — meaning the gap between where analysts sit and where the stock is trading is unusually wide by historical standards — while the dividend score reads 87, reflecting ABT's long track record of income consistency.
Positioning in the lending market is notably loose, which fits the picture of a stock where the bear thesis has softened even as the price has fallen. Short interest dropped nearly 10% over the past week to around 1.2% of free float, reversing a buildup that had pushed it briefly toward the 1.5% area in mid-April around the earnings event. Borrow availability is ample, and the cost to borrow of 0.37% remains well below any level that would indicate short-side pressure or squeeze dynamics. Options traders have edged slightly more defensive — the put/call ratio is 0.96, modestly above its 20-day average of 0.94 — but the z-score of 0.68 is well within normal range. The ORTEX short score of 28.9 ranks in the 82nd percentile for low short pressure, consistent with the message from borrow and availability data. This is a stock where short sellers pulled back after the earnings drop rather than pressing into it.
The next earnings event is scheduled for July 15. Between now and then, the key variables are whether the diabetes segment tender renewal materialises as expected in Q2, whether medical device volumes recover, and whether tariff-related cost headwinds — a concern flagged across the healthcare equipment sector in recent weeks — show up in guidance. The gap between the current price and the analyst consensus target is the widest it has been in some time, making the July print a significant reset event in either direction. With close peers SYK and PODD each down 2-5% on the week versus ABT's modest 1.2% gain, the stock has shown some relative resilience — the insider bid may be part of the reason.
See the live data behind this article on ORTEX.
Open ABT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
